Search Within

Paul Hamlin

Formats
  1. Meeting Abstract (183)
  2. Journal Article (101)
  3. Research Letter (7)
  4. Correspondence (1)
  5. Review (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Lymphoma (293)
  5. Population Sciences Research Program (152)
  6. Survivorship Research (145)

More Groups

People
  1. Andrew Zelenetz (186)
  2. Ariela Noy (144)
  3. Steven Horwitz (139)
  4. Maria Palomba (125)
  5. David Straus (122)
  6. Alison Moskowitz (119)

More People

Years
  1. 2025 (6)
  2. 2024 (24)
  3. 2023 (21)
  4. 2022 (12)
  5. 2021 (17)
  6. 2020 (13)

More Years

Publications
  1. Blood (125)
  2. Journal of Clinical Oncology (38)
  3. Hematological Oncology (15)
  4. Annals of Oncology (12)
  5. British Journal of Haematology (12)
  6. Haematologica (10)

More Publications

Publishers
  1. American Society of Hematology (134)
  2. American Society of Clinical Oncology (40)
  3. Wiley Blackwell (19)
  4. Elsevier Inc. (16)
  5. Oxford University Press (13)
  6. John Wiley & Sons (12)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • End-of-life care patterns in older patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting
    Meeting Abstract

    Hamlin, P. A.; Torka, P.; Hansen, E.; Belli, A. J.; Ambrose, J.; Zettler, C. M.; Fernandes, L. L.; Wiley, S.; Perry, B.; Wang, C. K.
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ferreira Lopes, A.; Hamlin, P. A.; Lue, J. K.; Ghione, P.; Owens, C.; Torka, P.; Kumar, A.; Steiner, R.; more...
    Blood (2024)

    Fulltext@MSK | Save